Compositions and Methods for Treating Bladder Cancer
AssigneeThe Regents of the University of Colorado, a body corporate
InventorsThomas Flaig, Arthur E. Frankel, Andrew Thorburn, L.Michael Glode, Jung Hee Woo, David Neville
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for treating bladder cancer. In particular, the present invention provides a fusion protein comprising a toxin moiety that is linked to an epithelial growth factor (EGF) moiety. The toxin moiety and the EGF moiety can be linked optionally via a linker. Typically, the fusion protein is administered intravesically into the cancerous bladder.
Claims7
A method for treating bladder cancer in a subject, said method comprising administering a diphtheria toxin epidermal growth factor (DT-EGF) fusion protein directly to a cancerous bladder of the subject.
A DT-EGF fusion protein comprising:
- (a) an N-terminal alanine;
- (b) no N-linked glycosylation site;
- and
- (c) a restriction site for subcloning in the pnPICZa yeast expression plasmid containing an alpha factor prepro leader sequence and the AOX1 promoter.
Dependencies are inferred from the claim text.